spinal muscular atrophy

脊髄性筋萎縮症 SMA

WordNet

1. work natural fibers into a thread; "spin silk"
2. prolong or extend; "spin out a visit" (同)spin out
3. the act of rotating rapidly; "he gave the crank a spin"; "it broke off after much twisting" (同)twirl, twist, twisting, whirl
4. a distinctive interpretation (especially as used by politicians to sway public opinion); "the campaign put a favorable spin on the story"
5. a short drive in a car; "he took the new car for a spin"
6. a swift whirling motion (usually of a missile)
7. revolve quickly and repeatedly around ones own axis; "The dervishes whirl around and around without getting dizzy" (同)spin around, whirl, reel, gyrate
8. form a web by making a thread; "spiders spin a fine web"
9. make up a story; "spin a yarn"
10. stream in jets, of liquids; "The creek spun its course through the woods"
11. twist and turn so as to give an intended interpretation; "The Presidents spokesmen had to spin the story to make it less embarrassing"
12. a decrease in size of an organ caused by disease or disuse (同)wasting, wasting away
13. undergo atrophy; "Muscles that are not used will atrophy"
14. any weakening or degeneration (especially through lack of use) (同)withering
15. of or relating to or consisting of muscle; "muscular contraction"
16. having or suggesting great physical power or force; "the muscular and passionate Fifth Symphony"
17. of or relating to the spine or spinal cord; "spinal cord"; "spinal injury"

PrepTutorEJDIC

1. (羊毛などから)〈糸など〉‘を'『紡ぐ』《+『名』+『out of』+『名』〈羊毛〉》,(糸などに)〈羊毛など〉‘を'紡ぐ《+『名』〈羊毛〉+『into』+『名』》 / 〈クモ・カイコなどが〉〈糸〉‘を'『吐く』;〈巣・繭〉‘を'かける / …‘を'くるくる回す / 〈物語など〉‘を'作る,話す / 『糸を紡ぐ』;〈クモ・カイコなどが〉糸を吐く / 〈こまなどが〉くるくる回る / 〈車などが〉疾走する / 〈頭などが〉くらくらする / 〈C〉〈U〉くるくる回すこと;回転 / 〈C〉《単数形で》(車などの)一走り / 〈C〉(飛行機の)きりもみ降下 / 〈C〉《単数形で》(価値などの)急落
2. (栄養不良などによる)萎縮(いしゅく) / (一般的に)衰退,退化 / 萎縮する,衰退する / …'を'萎縮させる,衰退させる
3. 『助肉の』,筋肉でできた / 筋肉による / 筋肉の発達した
4. 背骨の / せき髄麻酔

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/06/24 08:48:47」(JST)

wiki en

[Wiki en表示]

This article is about a genetic disorder associated with mutation in the SMN1 gene. For a list of other conditions with similar names, see Spinal muscular atrophies.

Spinal muscular atrophy
Location of neurons affected by spinal muscular atrophy in the spinal cord
Classification and external resources
Specialty	Medical genetics
ICD-10	G12.0-G12.1
ICD-9-CM	335.0-335.1
OMIM	253300 253550 253400 271150
DiseasesDB	14093 32911
MedlinePlus	000996
eMedicine	Spinal Muscular Atrophy Spinal Muscle Atrophy Kugelberg–Welander SMA
Patient UK	Spinal muscular atrophy
MeSH	D014897
GeneReviews	Spinal Muscular Atrophy

Spinal muscular atrophy (SMA), also called autosomal recessive proximal spinal muscular atrophy in order to distinguish it from other conditions with similar name – is a rare neuromuscular disorder characterised by loss of motor neurons and progressive muscle wasting, often leading to early death.

The disorder is caused by a genetic defect in the SMN1 gene, which encodes SMN, a protein widely expressed in all eukaryotic cells and necessary for survival of motor neurons. Diminished abundance of the protein results in loss of function of neuronal cells in the anterior horn of the spinal cord and subsequent system-wide muscle wasting (atrophy).

Spinal muscular atrophy manifests in various degrees of severity, which all have in common progressive muscle wasting and mobility impairment. Proximal muscles and lung muscles are affected first. Other body systems may be affected as well, particularly in early-onset forms of the disorder. SMA is the most common genetic cause of infant death.

Spinal muscular atrophy is an inherited disorder and is passed on in an autosomal recessive manner.

As of 2016, no pharmacological therapy is available for SMA, although works on an effective treatment are at an advanced stage.

Classification

SMA manifests over a wide range of severity, affecting infants through adults. The disease spectrum is variously divided into 3–5 types, in accordance either with the age of onset of symptoms or with the highest attained milestone of motor development.

The most commonly used classification is as follows:

Type	Eponym	Usual age of onset	Characteristics	OMIM
SMA1 (Infantile)	Werdnig–Hoffmann disease	0–6 months	The severe form manifests in the first months of life, usually with a quick and unexpected onset ("floppy baby syndrome"). Rapid motor neuron death causes inefficiency of the major bodily organs - especially of the respiratory system - and pneumonia-induced respiratory failure is the most frequent cause of death. Babies diagnosed with SMA type 1 do not generally live past two years of age, with death occurring as early as within weeks in the most severe cases (sometimes termed SMA type 0). With proper respiratory support, those with milder SMA type I phenotypes, which account for around 10% of SMA1 cases, are known to live into adolescence and adulthood.	253300
SMA2 (Intermediate)	Dubowitz disease	6–18 months	The intermediate form affects children who are never able to stand and walk but who are able to maintain a sitting position at least some time in their life. The onset of weakness is usually noticed some time between 6 and 18 months. The progress is known to vary greatly, some patients gradually grow weaker over time while others through careful maintenance avoid any progression. Scoliosis may be present in these children, and correction with a brace may help improve respiration. Body muscles are weakened, and the respiratory system is a major concern. Life expectancy is somewhat reduced but most SMA2 patients live well into adulthood.	253550
SMA3 (Juvenile)	Kugelberg–Welander disease	>12 months	The juvenile form usually manifests after 12 months of age and describes patients who are able to walk without support at some time, although many later lose this ability. Respiratory involvement is less noticeable, and life expectancy is normal or near normal.	253400
SMA4 (Adult-onset)		Adulthood	The adult-onset form (sometimes classified as a late-onset SMA type 3) usually manifests after the third decade of life with gradual weakening of muscles – mainly affects proximal muscles of the extremities – frequently requiring the patient to use a wheelchair for mobility. Other complications are rare, and life expectancy is unaffected.	271150

The most severe form of SMA type I is sometimes termed SMA type 0 (or, severe infantile SMA) and is diagnosed in babies that are born so weak that they can survive only a few weeks even with intensive respiratory support. SMA type 0 should not be confused with SMARD1 which may have very similar symptoms and course but has a different genetic cause than SMA.

Motor development in SMA patients is usually assessed using validated functional scales – CHOP INTEND (The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) in SMA1; and either the Motor Function Measure scale or one of a few variants of Hammersmith Functional Motor Scale in SMA types 2 and 3.

The eponymous label Werdnig–Hoffmann disease (sometimes misspelled with a single n) refers to the earliest clinical descriptions of childhood SMA by Johann Hoffmann and Guido Werdnig. The eponymous term Kugelberg–Welander disease is after Erik Klas Hendrik Kugelberg (1913-1983) and Lisa Welander (1909-2001), who distinguished SMA from muscular dystrophy. Rarely used Dubowitz disease (not to be confused with Dubowitz syndrome) is named after Victor Dubowitz, an English neurologist who authored several studies on the intermediate SMA phenotype.

Signs and symptoms

The symptoms vary greatly depending on the SMA type involved, the stage of the disease, and individual factors; they commonly include:

• Areflexia, particularly in extremities
• Overall muscle weakness, poor muscle tone, limpness or a tendency to flop
• Difficulty achieving developmental milestones, difficulty sitting/standing/walking
• In small children: adopting of a frog-leg position when sitting (hips abducted and knees flexed)
• Loss of strength of the respiratory muscles: weak cough, weak cry (infants), accumulation of secretions in the lungs or throat, respiratory distress
• Bell-shaped torso (caused by using only abdominal muscles for respiration) in weaker SMA types
• Fasciculations (twitching) of the tongue
• Difficulty sucking or swallowing, poor feeding

Causes

Spinal muscular atrophy has an autosomal recessive pattern of inheritance.

Spinal muscular atrophy is linked to a genetic mutation in the SMN1 gene.

Human chromosome 5 contains two nearly identical genes at location 5q13: a telomeric copy SMN1 and a centromeric copy SMN2. In healthy individuals, the SMN1 gene codes the survival of motor neuron protein (SMN) which, as its name says, plays a crucial role in survival of motor neurons. The SMN2 gene, on the other hand - due to a variation in a single nucleotide (840.C→T) - undergoes alternative splicing at the junction of intron 6 to exon 8, with only 10-20% of SMN2 transcripts coding a fully functional survival of motor neuron protein (SMN-fl) and 80-90% of transcripts resulting in a truncated protein compound (SMNΔ7) which is rapidly degraded in the cell.

In individuals affected by SMA, the SMN1 gene is mutated in such a way that it is unable to correctly code the SMN protein - due to either a deletion occurring at exon 7 or to other point mutations (frequently resulting in the functional conversion of the SMN1 sequence into SMN2). All patients, however, retain at least one copy of the SMN2 gene (with most having 2-4 of them) which still codes small amounts of SMN protein - around 10-20% of the normal level - allowing some neurons to survive. In the long run, however, reduced availability of the SMN protein results in gradual death of motor neuron cells in the anterior horn of spinal cord and the brain. Muscles that depend on these motor neurons for neural input now have decreased innervation (also called denervation), and therefore have decreased input from the central nervous system (CNS). Denervated skeletal muscle is more difficult for the body to control. Decreased impulse transmission through the motor neurons leads to decreased contractile activity of the denervated muscle. Consequently, denervated muscles undergo progressive atrophy.

Muscles of lower extremities are usually affected first, followed by muscles of upper extremities, spine and neck and, in more severe cases, pulmonary and mastication muscles. Proximal muscles are always affected earlier and to a greater degree than distal.

The severity of SMA symptoms is broadly related to how well the remaining SMN2 genes can make up for the loss of function of SMN1. This is partly related to the number of SMN2 gene copies present on the chromosome. Whilst healthy individuals carry two SMN2 gene copies, patients with SMA can have anything between 1 and 4 (or more) of them, with the greater the number of SMN2 copies, the milder the disease severity. Thus, most SMA type I babies have one or two SMN2 copies; SMA II and III patients usually have at least three SMN2 copies; and SMA IV patients normally have at least four of them. However, the correlation between symptom severity and SMN2 copy number is not absolute, and there seem to exist other factors affecting the disease phenotype.

Spinal muscular atrophy is inherited in an autosomal recessive pattern, which means that the defective gene is located on an autosome. Two copies of the defective gene - one from each parent - are required to inherit the disorder: the parents may be carriers and not personally affected. SMA seems to appear de novo (i.e., without any hereditary causes) in around 2-4% of cases.

Spinal muscular atrophy affects individuals of all ethnic groups, unlike other well known autosomal recessive disorders, such as sickle cell disease and cystic fibrosis, which have significant differences in occurrence rate among ethnic groups. The overall prevalence of SMA, of all types and across all ethnic groups, is in the range of 1 per 10,000 individuals; the gene frequency is around 1:100, therefore, approximately one in 50 persons are carriers. There are no known health consequences of being a carrier. A person may learn carrier status only if one's child is affected by SMA or by having the SMN1 gene sequenced.

Affected siblings usually have a very similar form of SMA. However, occurrences of different SMA types among siblings do exist – while rare, these cases might be due to additional de novo deletions of the SMN gene, not involving the NAIP gene, or the differences in SMN2 copy numbers.

Diagnosis

Very severe SMA (type 0/1) can be sometimes evident before birth - reduction in foetal movement in the final months of pregnancy. Otherwise SMA1 manifests within the first few weeks or months of life when abnormally low muscle tone is observed in the infant (the "floppy baby syndrome").

For all SMA types,

• Patient will present hypotonia associated with absent reflexes;
• Electromyogram will show fibrillation and muscle denervation;
• Serum creatine kinase may be normal or increased;

While the above symptoms point towards SMA, the diagnosis can only be confirmed with absolute certainty through genetic testing for bi-allelic deletion of exon 7 of the SMN1 gene. Genetic test is usually carried out using a blood sample, and MLPA is one of more frequently used techniques as it also allows establishing the number of SMN2 gene copies.

Preimplantation testing

Preimplantation genetic diagnosis can be used to detect SMA-affected foetuses, especially when undergoing in-vitro fertilisation.

Prenatal testing

Prenatal testing towards SMA is possible through chorionic villus sampling, cell-free fetal DNA analysis and other methods.

Carrier testing

Those at risk of being carriers of SMN1 deletion, and thus at risk of having offspring affected by SMA, can undergo carrier analysis using blood or saliva sample.

Routine screening

Routine prenatal or neonatal screening for SMA is controversial, because of the cost and because of the severity of the disease as well as lack of approved treatment. Some researchers have concluded that population screening for SMA is not cost-effective, at a cost of $5 million per case averted in USA. Others conclude that SMA meets the criteria for screening programs and relevant testing should be offered to all couples.

Management

There is no pharmacological treatment to spinal muscular atrophy. Care is symptomatic. Main areas of concern are as follows:

Orthopaedics

Weak spine muscles may lead to development of kyphosis, scoliosis and other orthopaedic problems. Spine fusion is sometimes performed in SMA I/II patients once they reach the age of 8-10 to relieve the pressure of a deformed spine on the lungs. Patients with SMA might also benefit greatly from various forms of physiotherapy and occupational therapy.

Mobility support

Orthotic devices can be used to support the body and to aid walking. For example, orthotics such as AFO's (ankle foot orthosis) are used to stabilise the foot and to aid gait, TLSO's (thoracic lumbar sacral orthosis) are used to stabilise the torso. Assistive technologies may help in managing movement and daily activity and greatly increase the quality of life.

Respiratory care

Respiratory system requires utmost attention in SMA as once weakened it never fully recovers. Weakened pulmonary muscles in SMA type I/II patients can make breathing more difficult and pose a risk of hypoxiation, especially in sleep when muscles are more relaxed. Impaired cough reflex poses a constant risk of respiratory infection and pneumonia. Non-invasive ventilation (BiPAP) is frequently used and tracheostomy may be sometimes performed in more severe cases; both methods of ventilation prolong survival in a comparable degree, although tracheostomy prevents speech development.

Nutrition

Difficulties in jaw opening, chewing and swallowing food might put patients with SMA at risk of malnutrition. A feeding tube or gastrostomy can be necessary in SMA type I and more severe type II patients. Additionally, metabolic abnormalities resulting from SMA impair β-oxidation of fatty acids in muscles and can lead to organic acidemia and consequent muscle damage, especially when fasting. It is suggested that patients with SMA, especially those with more severe forms of the disease, reduce intake of fat and avoid prolonged fasting (i.e., eat more frequently than healthy people).

Cardiology

Although heart is not a matter of routine concern, a link between SMA and certain heart conditions has been suggested.

Mental health

SMA children do not differ from the general population in their behaviour; their cognitive development can be slightly faster, and certain aspects of their intelligence are above the average. Despite their disability, SMA-affected people report high degree of satisfaction from life.

Palliative care in SMA has been standardised in the Consensus Statement for Standard of Care in Spinal Muscular Atrophy which has been recommended for standard adoption worldwide.

Prognosis

Generally, patients tend to deteriorate over time, but prognosis varies with the SMA type and disease progress which shows a great degree of individual variability.

The majority of children diagnosed with SMA type 0 and 1 do not reach the age of 4, recurrent respiratory problems being the primary cause of death. With proper care, milder SMA type 1 cases (which account for approx. 10% of all SMA1 cases) live into adulthood. Long-term survival in SMA1 is not sufficiently evidenced; however, recent advances in respiratory support seem to have brought down mortality.

In SMA type 2, the course of the disease is stable or slowly progressing and life expectancy is reduced compared to the healthy population. Death before the age of 20 is frequent, although many patients live to become parents and grandparents. SMA type 3 has normal or near-normal life expectancy if standards of care are followed. Adult-onset SMA usually means only mobility impairment and does not affect life expectancy.

In all SMA types, physiotherapy has been shown to delay the progress of disease.

Research directions

Since the underlying genetic mechanism of SMA was described in 1990, several therapeutic approaches have been proposed and investigated which primarily focused on increasing the availability of SMN protein to motor neurons.. The main research directions are as follows:

SMN1 gene replacement

Gene therapy in SMA aims at restoring the SMN1 gene function through inserting specially crafted nucleotide sequence (a SMN1 transgene) with the help of a viral vector; scAAV-9 and scAAV-10 are the primary viral vectors under investigation.

Only one programme has reached the clinical stage:

• AVXS-101 – a proprietary biologic under development by Avexis, using scAAV-9 vector. As of May 2016, it remained in phase I clinical trial, with published results showing marked improvement in treated infants compared to the natural course of the disorder.

Work on developing gene therapy for SMA is also conducted at the Institut de Myologie in Paris and at Genzyme Corporation.

SMN2 alternative splicing modulation

This approach aims at modifying the alternative splicing of the SMN2 gene so that to force it to code for higher percentage of full-length SMN protein. Sometimes it is also called gene conversion, because it attempts to convert the SMN2 gene functionally into SMN1 gene.

The following splicing modulators have reached clinical stage development:

• Nusinersen (formerly, IONIS-SMNR_x, ISIS-SMNR_x) – a proprietary antisense oligonucleotide developed by Ionis Pharmaceuticals and Biogen. As of 2016, in phase III clinical trials, after showing promise in phase II clinical trials in infants and children with SMA types 1, 2 and non-ambulant 3. The drug is administered directly to the central nervous system using an intrathecal injection once every few months.
• RG7800 and RG7916 – proprietary small-molecule drugs administered orally developed by PTC Therapeutics and Hoffmann-La Roche. As of 2016, clinical development of RG7800 has been put on hold due to animal toxicity while RG7916 is advancing to phase II trials across all patient ages and SMA types.
• LMI070 – a proprietary small-molecule drug administered orally, being developed by Novartis. As of 2016 the drug remains in phase I–II trials in infants with SMA type 1.

Of discontinued clinical-stage molecules, RG3039, also known as Quinazoline495, was a proprietary quinazoline derivative developed by Repligen and licensed to Pfizer in March 2014 which was discontinued shortly after, having only completed phase I trials. PTK-SMA1 was a proprietary small-molecule splicing modulator of the tetracyclines group developed by Paratek Pharmaceutical and about to enter clinical development in 2010 which was however discontinued.

Basic research has also identified other compounds which modified SMN2 splicing in vitro, like sodium orthovanadate and aclarubicin. Morpholino-type antisense oligonucleotides remain in pre-clinical studies at the University College London.

SMN2 gene activation

This approach aims at increasing expression (activity) of the SMN2 gene, thus increasing the amount of full-length SMN protein available.

• Oral salbutamol (albuterol), a popular asthma medicine, showed therapeutic potential in SMA both in vitro and in three small-scale clinical trials involving patients with SMA types 2 and 3, besides offering respiratory benefits.

A few compounds initially showed promise but turned out ineffective upon more extensive research:

• Butyrates (sodium butyrate and sodium phenylbutyrate) held some promise in in vitro studies but a clinical trial in symptomatic patients did not confirm their efficacy. Another clinical trial in pre-symptomatic types 1–2 infants was completed in 2015 but no results have been published.
• Valproic acid was widely used in SMA on experimental basis in the 1990s and 2000s because in vitro research suggested its moderate effectiveness. However, it had no efficacy in achievable concentrations when subjected to a large clinical trial. Some research suggests it may actually aggravate SMA symptoms.
• Hydroxycarbamide (hydroxyurea) was shown effective in mouse models and subsequently commercially researched by Novo Nordisk, Denmark, but demonstrated no effect on SMA patients in subsequent clinical trials.

Compounds which increased SMN2 activity in vitro but did not make it to the clinical stage include growth hormone, various histone deacetylase inhibitors, benzamide M344, hydroxamic acids (CBHA, SBHA, entinostat, panobinostat, trichostatin A, vorinostat), prolactin as well as natural polyphenol compounds like resveratrol and curcumin.

SMN stabilisation

SMN stabilisation aims at stabilising the SMNΔ7 protein, the short-lived defective protein coded by the SMN2 gene, so that it is able to sustain neuronal cells.

No compounds have been taken forward to the clinical stage. Aminoglycosides showed capability to increase SMN protein availability in two studies. Indoprofen offered some promise in vitro.

Neuroprotection

Neuroprotective drugs aim at enabling the survival of motor neurons even with low levels of SMN protein.

• Olesoxime – a proprietary neuroprotective compound developed by the French company Trophos which showed stabilising effect in a phase II–III clinical trial involving patients with SMA types II and III. The drug is being developed by Hoffmann-La Roche since its acquisition of Trophos in early 2015.
• Riluzole – a compound offering mild benefit in amyotrophic lateral sclerosis with some indications it could work in SMA. A clinical trial of riluzole in SMA types 2 and 3 was conducted in 2008–2013, with no results published.

Thyrotropin-releasing hormone (TRH) showed some promise in an open-label uncontrolled clinical trial but did not prove effective in a subsequent double-blind placebo-controlled trial.

Compounds that had some neuroprotective effect in in vitro studies of SMA but never moved to the clinical stage include β-lactam antibiotics (e.g., ceftriaxone) and follistatin.

Muscle restoration

This approach aims to counter the effect of SMA by helping to restore or re-grow the lost muscle tissue.

• CK-2127107 is a compound developed by Cytokinetics. As of 2016, it has completed a phase I clinical trial and is scheduled to undergo further trials.

Stem cells

As of 2016, there has been no significant breakthrough in stem cell therapy in SMA. An experimental programme to develop a stem cell based therapeutic product for SMA was run by a US company California Stem Cell since 2005, with financial support from the SMA community. The programme was ended in 2010, unable to enter human clinical trials, and the company ceased to exist shortly after. In 2013–2014, a number of SMA1 children in Italy received court-mandated stem cell injections as a result of Stamina scam, but the treatment was reported having no effect.

Whilst stem cells never form a part of any recognised therapy for SMA, a number of private companies, usually located in countries with lax regulatory oversight, sell stem cell injections as a "cure" for a vast number of disorders, including SMA. The medical consensus is that such procedures offer no benefit whilst carrying significant risk, therefore patients are advised against them.

Patient registries

Patients with SMA can avail of an opportunity of participating in clinical research by entering their details into SMA patient registries managed by TREAT-NMD.

See also

• SMA Treatment Acceleration Act
• Spinal muscular atrophies
• Motor neuron disease

References

Further reading

• Parano, E; Pavone, L; Falsaperla, R; Trifiletti, R; Wang, C (Aug 1996). "Molecular basis of phenotypic heterogeneity in siblings with spinal muscular atrophy.". Annals of Neurology 40 (2): 247–51. doi:10.1002/ana.410400219. PMID 8773609. 

External links

• SMA at NINDS
• Spinal muscular atrophy at DMOZ
• Standards of Care in Spinal Muscular Atrophy

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 脊髄性筋萎縮症 spinal muscular atrophy
• 2. 新生児における筋緊張低下を引き起こす末梢神経および筋肉の障害に関する概要 overview of peripheral nerve and muscle disorders causing hypotonia in the newborn
• 3. Etiology and evaluation of the child with weakness
• 4. 筋萎縮性側索硬化症およびその他の運動ニューロン疾患の診断 diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease
• 5. 肢帯型筋ジストロフィー limb girdle muscular dystrophy

English Journal

• Diversity in the androgen receptor CAG repeat has been shaped by a multistep mutational mechanism.

• Santos D1, Pimenta J, Wong VC, Amorim A, Martins S.
• American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.Am J Med Genet B Neuropsychiatr Genet.2014 Oct;165(7):581-6. doi: 10.1002/ajmg.b.32261. Epub 2014 Jul 31.
• The androgen receptor (AR) gene encodes a type of nuclear receptor that functions as a steroid-hormone activated transcription factor. In its coding region, AR includes a CAG repeat, which has been intensely studied due to the inverse correlation between repeat size and AR transcriptional activity.
• PMID 25078541

• Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients.

• Grunseich C1, Zukosky K2, Kats IR3, Ghosh L4, Harmison GG5, Bott LC6, Rinaldi C7, Chen KL8, Chen G9, Boehm M10, Fischbeck KH11.
• Neurobiology of disease.Neurobiol Dis.2014 Oct;70:12-20. doi: 10.1016/j.nbd.2014.05.038. Epub 2014 Jun 9.
• Spinal and bulbar muscular atrophy (SBMA, Kennedy's disease) is a motor neuron disease caused by polyglutamine repeat expansion in the androgen receptor. Although degeneration occurs in the spinal cord and muscle, the exact mechanism is not clear. Induced pluripotent stem cells from spinal and bulba
• PMID 24925468

• Neurologic disease with pregnancy and considerations for the obstetric anesthesiologist.

• Hopkins AN1, Alshaeri T2, Akst SA1, Berger JS3.
• Seminars in perinatology.Semin Perinatol.2014 Oct;38(6):359-369. doi: 10.1053/j.semperi.2014.07.004. Epub 2014 Aug 28.
• Women with neurologic conditions present a challenge during pregnancy and in the peripartum period. Given the low prevalence of these diseases during pregnancy, most management decisions are guided by retrospective reviews and case reports. This article reviews current literature for some of the mor
• PMID 25176638

Japanese Journal

• 球脊髄性筋萎縮症に対するdisease-modifying therapy (第1土曜特集 神経変性疾患 : 研究と診療の進歩) -- (神経変性疾患の治療の新しい展開)

• 鈴木 啓介,勝野 雅央,祖父江 元
• 医学のあゆみ 247(5), 479-485, 2013-11-02
• NAID 40019848725

• 脊髄性筋萎縮症の遺伝カウンセリング

• 浦野 真理,齋藤 加代子,URANO Mari,SAITO Kayoko
• 東京女子医科大学雑誌 83(E3), E651-E655, 2013-07-31
• … 本稿では脊髄性筋萎縮症(Spinal Muscular Atrophy)の遺伝カウンセリングについて述べる。 …
• NAID 110009604922

• 脊髄性筋萎縮症の遺伝カウンセリング (医学部小児科学教室 大澤眞木子教授退任記念特別号(2))

• 浦野 真理,齋藤 加代子
• 東京女子医科大学雑誌 83 (臨増), E651-655, 2013-07
• NAID 40019795646

Related Links

• Spinal Muscular Atrophy | Muscular Dystrophy Association

Spinal Muscular Atrophy What is spinal muscular atrophy? Spinal muscular atrophy (SMA) is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement. Most of the nerve cells that control ...

• Spinal Muscular Atrophy | SMA | MedlinePlus

Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These cells communicate with your voluntary muscles - the ones you can control, like in your arms and legs. As ...

Related Pictures

---

★リンクテーブル★

リンク元	「脊髄性筋萎縮症」「SMA」「progressive muscular atrophy」
拡張検索	「distal spinal muscular atrophy」
関連記事	「spinal」「muscular」「spin」「atrophy」

「脊髄性筋萎縮症」

　　[★]

英

spinal muscular atrophy, SMA

同？

脊髄進行性筋萎縮症 progressive spinal muscular atrophy

関

筋萎縮、運動ニューロン疾患, motor neuron disease, MND

運動ニューロン病

BET.439

• 上位運動ニューロン and/or 下位運動ニューロンが選択的に傷害される疾患の総称

上位運動ニューロン障害	原発性側索硬化症 PLS
上位+下位運動ニューロン障害	筋萎縮性側索硬化症 ALS		孤発性/家族性
下位運動ニューロン障害	脊髄性筋萎縮症 SMA	SMA type 1, infantile SMA, Werdnig-Hoffmann disease ウェルドニッヒ・ホフマン病 WH	AR
		SMA type 2, intermediate SMA
		SMA type 3, juvenile SMA, Kugelberg-Welander disease クーゲルベルク・ウェランダー病 KW	AR
	球脊髄性筋萎縮症 BSMA Kennedy-Alter-Sung disease ケネディ・オルター・スン症候群 KAS		XR、CAGリピート

遺伝形式

• 常染色体劣性遺伝

原因遺伝子

• 5q13.2に座乗するSMN1遺伝子の変異。

症状

• 下位運動ニューロンの脱落・変性
• 近位筋優位の筋萎縮　　　←　　　神経原性の筋萎縮なのに・・・　　(cf. 筋萎縮)

参考

uptodate

• 1. [charged] 脊髄性筋萎縮症 - uptodate [1]

OMIM

• 1. SPINAL MUSCULAR ATROPHY, TYPE I; SMA1, Gene map locus 5q12.2-q13.3

http://omim.org/entry/253300

• 2. SPINAL MUSCULAR ATROPHY, TYPE II; SMA2, Gene map locus 5q12.2-q13.3

http://omim.org/entry/253550

• 3. SPINAL MUSCULAR ATROPHY, TYPE III; SMA3, Gene map locus 5q12.2-q13.3, 5q12.2-q13.3

http://omim.org/entry/253400

• 4. SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4, Gene map locus 5q12.2-q13.3

http://omim.org/entry/271150

「SMA」

　　[★]

• 脊髄性筋萎縮症 spinal muscular atrophy
• 上腸間膜動脈 superior mesenteric artery
• 補足運動野 supplementary motor area
• 自発運動活性 spontaneous motor activity = locomotor activity

「progressive muscular atrophy」

　　[★] 進行性筋萎縮症、進行性筋萎縮

関

bulbospinal neuronopathy、distal spinal muscular atrophy、Kennedy syndrome、spinal muscular atrophy

「distal spinal muscular atrophy」

　　[★]

遠位型脊髄性筋萎縮症、遠位型脊髄性筋萎縮

関

bulbospinal neuronopathy、Kennedy syndrome、progressive muscular atrophy、spinal muscular atrophy

「spinal」

　　[★]

• adj.

• 脊髄の、脊髄性の、脊柱の

関

dorsal spine、rachis、spinal column、spinal cord、spine、vertebral column

　 　

「muscular」

　　[★]

• adj.

• 筋肉の、筋の

関

muscle、muscularis、musculus、myo

　 　 　

「spin」

　　[★]

• スピン

　 　 　 　 　 　 　 　 　 　 　 　

「atrophy」

　　[★]

• n.

• 萎縮